Lipocine Inc (LPCN)
4.68
-0.02
(-0.43%)
USD |
NASDAQ |
May 03, 16:00
4.60
-0.08
(-1.71%)
After-Hours: 20:00
Lipocine Research and Development Expense (Quarterly)
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2023 | 2.879M |
| June 30, 2023 | |
| March 31, 2023 | 3.106M |
| December 31, 2022 | |
| September 30, 2022 | 2.100M |
| June 30, 2022 | |
| March 31, 2022 | 1.888M |
| December 31, 2021 |
| Date | Value |
|---|---|
| September 30, 2021 | |
| June 30, 2021 | |
| March 31, 2021 | 1.580M |
| December 31, 2020 | |
| September 30, 2020 | |
| June 30, 2020 | |
| March 31, 2020 | 2.512M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
1.580M
Minimum
Mar 2021
3.106M
Maximum
Mar 2023
2.344M
Average
2.306M
Median
Research and Development Expense (Quarterly) Benchmarks
| Alpine Immune Sciences Inc | 22.93M |
| Eliem Therapeutics Inc | 3.127M |
| NovaBay Pharmaceuticals Inc | 0.004M |
| Palatin Technologies Inc | 5.554M |
| iBio Inc | 1.535M |